Navigation Links
LUMA Cervical Imaging System Installed in Edina at Minnesota Gynecology
Date:2/18/2009

First in the State of Minnesota

MINNEAPOLIS, Feb. 18 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a medical device company, today announced that it will place its LUMA(R) Cervical Imaging System to detect pre-cancers at Minnesota Gynecology and Surgery, located in Edina, Minnesota.

Dr. James B. Presthus, co-founder of Minnesota Gynecology and Surgery, stated "The introduction of the LUMA System represents our continued dedication in providing the best care possible for our patients. The LUMA System gives our practice a unique and powerful tool when following up on abnormal Pap test results. We have always been on the leading edge of new technologies, and with the LUMA System our patients will experience improved outcomes from earlier detection of pre-cancers of the cervix and, therefore, earlier treatment. For the first time, this device gives us objective tissue diagnosis capability as compared to today's subjective interpretation methods. We are the first practice in Minnesota to offer the non-invasive LUMA test."

The LUMA Cervical Imaging System was developed to significantly improve the detection of high-grade precancerous cervical abnormalities that have the potential to become invasive cancer. Based on data from the National ALTS study, it is estimated that precancerous cervical disease goes undiagnosed in about 200,000 American women each year. The LUMA System provides a safe, non-invasive and effective method, that when used as an adjunct to colposcopy, has been demonstrated to uncover at least 26% more high-grade precancerous disease than colposcopy alone.

SpectraScience CEO Jim Hitchin commented, "We are pleased to have placed our LUMA System at Minnesota Gynecology and Surgery. This placement represents our continued dedication in developing and bringing more effective cancer screening technologies to the market with the result of better and earlier diagnosis thus saving lives."

SpectraScience has filed for 60 patents worldwide on its WavSTAT(R) Optical Biopsy System and LUMA Cervical Cancer Imaging System that are used to diagnose tissue to determine within seconds if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA systems are currently approved by the FDA for detecting pre-cancer and cancer in the colon and cervix, and an evaluation for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA(R) Cervical Imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available today.

    Contact:
    SpectraScience, Inc.
    Jim Hitchin, Chief Executive Officer
    (858) 847-0200 x 201
   http://www.spectrascience.com

    Hayden Communications
    Investor Relations
    Todd Pitcher
    (858)-518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Local TV Ad Campaign To Educate St. Louis Women About Cervical Cancer Prevention and HPV Testing
2. New Local TV Ad Campaign To Educate Memphis Women About Cervical Cancer Prevention and HPV Testing
3. HPV18 DNA levels are not prognostic for precancerous cervical lesions
4. Photos: Despite Widespread Awareness, Most Women Still Dont Feel at Risk for Cervical Cancer
5. U.S. and European Advocacy Groups Launch United, Global Campaign to Prevent Cervical Cancer
6. Multiple Screening Strategy Boosts Cervical Cancer Detection
7. The PA Breast Cancer Coalition Urges You to Donate Your State Income Tax Refund to Breast and Cervical Cancer Research
8. Department of Health Recognizes January As Cervical Health Awareness Month
9. Fears of promiscuity pose barrier to cervical cancer vaccinations
10. Male circumcision may decrease risk of HPV infection and cervical cancer
11. Cervical Cancer Vaccine Well Tolerated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
Breaking Medicine Technology: